Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
BAALC was identified by gene expression studies in patients with acute myeloid leukemia (AML). Zusätzlich bieten wir Ihnen BAALC Proteine (8) und BAALC Kits (4) und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 45 products:
Human Polyclonal BAALC Primary Antibody für ELISA, WB - ABIN250807
Satoskar, Tanner, Weinstein, Qualman, de la Chapelle: Baalc, a marker of mesoderm and muscle. in Gene expression patterns : GEP 2005
Human Monoclonal BAALC Primary Antibody für ELISA, WB - ABIN529108
Ikeda, Ageta, Tsuchida, Yamada: iTRAQ-based proteomics reveals novel biomarkers of osteoarthritis. in Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2013
BAALC expression-based minimal residual disease detection during therapy may be considered a strategy to identify patients at high risk of relapse.
Study provide evidence for an association of rs62527607 [GT] SNP of BAALC gene with multidrug resistance in childhood ALL.
BAALC and ERG (zeige ERG Antikörper) genes are specific significant molecular markers in acute myeloid leukemia (zeige BCL11A Antikörper) disease progression, response to treatment and survival.
demonstrated that BAALC blocks ERK (zeige EPHB2 Antikörper)-mediated monocytic differentiation of acute myeloid leukemia (zeige BCL11A Antikörper) cells by trapping Kruppel-like factor 4 (KLF4 (zeige KLF4 Antikörper)) in the cytoplasm and inhibiting its function in the nucleus
combined determination of both miR (zeige MLXIP Antikörper)-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers
study indicates that overexpression of BAALC serves as an independent prognostic biomarker in acute myeloid leukemia (zeige BCL11A Antikörper)
Evaluating WT1 (zeige WT1 Antikörper) and BAALC gene expression at diagnosis may improve standard risk stratification and possibly refine the therapeutic approach for Myelodysplastic Syndromes patients.
Thus low MDR1 (zeige TBC1D9 Antikörper)/low BAALC expression identifies a subgroup of intermediate cytogenetic risk AML (zeige RUNX1 Antikörper) patients with a remarkably good long-term outcome achieved by chemotherapy alone.
miR (zeige MLXIP Antikörper)-3151 introns within BAALC have roles in driving leukemogenesis by deregulating the TP53 (zeige TP53 Antikörper) pathway
Higher BAALC expression and FLT3 (zeige FLT3 Antikörper)-ITD mutation, both individually and in combination, were associated with worse survival outcomes in CN-AML (zeige RUNX1 Antikörper), and this was also applicable in NPM1 (zeige NPM1 Antikörper)-mutated CN-AML (zeige RUNX1 Antikörper), known as a favorable-risk group.
BAALC/Baalc is a marker of the mesodermal lineage, especially muscle.
This gene was identified by gene expression studies in patients with acute myeloid leukemia (AML). The gene is conserved among mammals and is not found in lower organisms. Tissues that express this gene develop from the neuroectoderm. Multiple alternatively spliced transcript variants that encode different proteins have been described for this gene\; however, some of the transcript variants are found only in AML cell lines.
brain and acute leukemia cytoplasmic protein
, brain and acute leukemia, cytoplasmic